Funding for early-stage biomedical innovation has become more difficult to secure at the same time that medical breakthroughs seem to be occurring at ever increasing rates. One explanation for this counterintuitive trend is that increasing scientific knowledge can actually lead to greater economic risk for investors in the life sciences. While the Human Genome Project, high-throughput screening, genetic biomarkers, immunotherapies, and gene therapies have made a tremendously positive impact on biomedical research and, consequently, patient lives, they have also increased the cost and complexity of the drug development process, causing many investors to shift their assets to more attractive investment opportunities. This suggests that new business models and financing strategies can be used to reduce the risk and increase the attractiveness of biomedical innovation so as to bring new and better therapies to patients faster.
Keyphrases
- early stage
- healthcare
- genome wide
- end stage renal disease
- newly diagnosed
- ejection fraction
- copy number
- endothelial cells
- papillary thyroid
- peritoneal dialysis
- gene expression
- case report
- prognostic factors
- dna methylation
- squamous cell carcinoma
- patient reported outcomes
- squamous cell
- childhood cancer
- sentinel lymph node
- pluripotent stem cells
- rectal cancer
- patient reported
- locally advanced